Phaseline

Companies › Keymed Biosciences Co.Ltd

Keymed Biosciences Co.Ltd: clinical trials, targets and expected readouts

9 active drug programs in 17 registered trials: 8 Phase 1, 8 Phase 2, 1 Phase 3; Oncology, Immunology, Hematology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CM310
IL-4 receptor (IL-4Rα) monoclonal antibody
IL4RPhase 3Atopic Dermatitis–
CM336
BCMA/CD3 bispecific antibody
BCMA, CD3E, TNFRSF17Phase 2Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous DiseaseDec 2026
CM512 injection–Phase 2Atopic Dermatitis; Chronic Spontaneous Urticaria (CSU); Asthma; Atopic Dermatitis (AD)Jan 2027
CM338–Phase 2IgA NephropathyJun 2027
CM313(SC) injection–Phase 2Primary Immune Thrombocytopenia; Platelet Transfusion RefractorinessNov 2027
CM383–Phase 1Healthy; Alzheimer DiseaseDec 2026
CM350
anti-GPC3 antibody
GPC3Phase 1Advanced Solid TumorApr 2027
CM518D1–Phase 1Advanced Solid TumorsDec 2028
CM559–Phase 1Healthy Subjects–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06594146CM313(SC) injectionPhase 2Primary Immune ThrombocytopeniaHematologyDec 2025
NCT07175506CM559Phase 1Healthy SubjectsOtherJun 2026
NCT07292688CM383Phase 1HealthyOtherJul 2026
NCT06947980CM512 injectionPhase 2Atopic DermatitisImmunologyJul 2026
NCT06495229CM310Phase 3Atopic DermatitisImmunologyAug 2026
NCT05299424CM336Phase 1Multiple MyelomaOncologyDec 2026
NCT06619613CM383Phase 1Alzheimer DiseaseNeurologyDec 2026
NCT06900010CM336Phase 2Autoimmune Bullous DiseaseImmunologyJan 2027
NCT07166211CM512 injectionPhase 2Chronic Spontaneous Urticaria (CSU)ImmunologyJan 2027
NCT05263960CM350Phase 1Advanced Solid TumorOncologyApr 2027
NCT05775042CM338Phase 2IgA NephropathyGenitourinaryJun 2027
NCT07011524CM512 injectionPhase 2AsthmaRespiratoryJul 2027
NCT06792019CM313(SC) injectionPhase 1Platelet Transfusion RefractorinessHematologyNov 2027
NCT07175493CM336Phase 1Autoimmune CytopeniaHematologyNov 2027
NCT07230483CM512 injectionPhase 2Atopic Dermatitis (AD)ImmunologyDec 2027
NCT07019779CM518D1Phase 1Advanced Solid TumorsOncologyDec 2028
NCT07039578CM336Phase 2Primary Light-Chain AmyloidosisMetabolic and endocrineJul 2029

Targets

GPC3 (1) BCMA (1) CD3E (1) TNFRSF17 (1) IL4R (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development iCell Gene Therapeutics AbbVie Roche Chongqing Precision Biotech Gracell Biotechnologies (Shanghai) Excyte Biopharma

Companies built like this

Genrix (Shanghai) Biopharmaceutical Suzhou Zelgen Biopharmaceuticals argenx Miltenyi Biomedicine Ipsen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.